N-body models of globular clusters: metallicity, half-light radii and mass-to-light ratios

Size differences of approx. 20% between red (metal-rich) and blue (metal-poor) sub-populations of globular clusters have been observed, generating an ongoing debate as to weather these originate from projection effects or the difference in metallicity. We present direct N-body simulations of metal-rich and metal-poor stellar populations evolved to study the effects of metallicity on cluster evolution. The models start with N = 100000 stars and include primordial binaries. We also take metallicity dependent stellar evolution and an external tidal field into account. We find no significant difference for the half-mass radii of those models, indicating that the clusters are structurally similar. However, utilizing observational tools to fit half-light (or effective) radii confirms that metallicity effects related to stellar evolution combined with dynamical effects such as mass segregation produce an apparent size difference of 17% on average. The metallicity effect on the overall cluster luminosity also leads to higher mass-to-light ratios for metal-rich clusters.Comment: 14 pages, 10 figures, accepted for publication in MNRA

Association football and the representation of homosexuality by the print media: a case study of Anton Hysén

In March 2011 Anton Hysén (a semi-professional footballer currently playing in the Swedish fourth division) became only the second association football (soccer) player of any professional disposition to publicly declare his homosexuality whilst still playing the game. This article provides a textual analysis of the print media’s reaction to Hysén coming out and examines whether, in 2011, they portray more inclusive notions towards homosexuality than they did in 1990 when British footballer Justin Fashanu came out. The results advance inclusive masculinity theory as a number of print media sources (mostly British) interview Hysén in the weeks immediately after he came out and publish articles that challenge homophobia. Highlighting a change since 1990, a significant number of articles stress the need for the key stakeholders in football (players, fans, clubs, agents, the authorities and the media) to accept gay players

Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort

\ua9 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 licenseBackground: Individuals with rare kidney diseases account for 5–10% of people with chronic kidney disease, but constitute more than 25% of patients receiving kidney replacement therapy. The National Registry of Rare Kidney Diseases (RaDaR) gathers longitudinal data from patients with these conditions, which we used to study disease progression and outcomes of death and kidney failure. Methods: People aged 0–96 years living with 28 types of rare kidney diseases were recruited from 108 UK renal care facilities. The primary outcomes were cumulative incidence of mortality and kidney failure in individuals with rare kidney diseases, which were calculated and compared with that of unselected patients with chronic kidney disease. Cumulative incidence and Kaplan–Meier survival estimates were calculated for the following outcomes: median age at kidney failure; median age at death; time from start of dialysis to death; and time from diagnosis to estimated glomerular filtration rate (eGFR) thresholds, allowing calculation of time from last eGFR of 75 mL/min per 1\ub773 m2 or more to first eGFR of less than 30 mL/min per 1\ub773 m2 (the therapeutic trial window). Findings: Between Jan 18, 2010, and July 25, 2022, 27 285 participants were recruited to RaDaR. Median follow-up time from diagnosis was 9\ub76 years (IQR 5\ub79–16\ub77). RaDaR participants had significantly higher 5-year cumulative incidence of kidney failure than 2\ub781 million UK patients with all-cause chronic kidney disease (28% vs 1%; p<0\ub70001), but better survival rates (standardised mortality ratio 0\ub742 [95% CI 0\ub732–0\ub752]; p<0\ub70001). Median age at kidney failure, median age at death, time from start of dialysis to death, time from diagnosis to eGFR thresholds, and therapeutic trial window all varied substantially between rare diseases. Interpretation: Patients with rare kidney diseases differ from the general population of individuals with chronic kidney disease: they have higher 5-year rates of kidney failure but higher survival than other patients with chronic kidney disease stages 3–5, and so are over-represented in the cohort of patients requiring kidney replacement therapy. Addressing unmet therapeutic need for patients with rare kidney diseases could have a large beneficial effect on long-term kidney replacement therapy demand. Funding: RaDaR is funded by the Medical Research Council, Kidney Research UK, Kidney Care UK, and the Polycystic Kidney Disease Charity

Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort

Background Individuals with rare kidney diseases account for 5–10% of people with chronic kidney disease, but constitute more than 25% of patients receiving kidney replacement therapy. The National Registry of Rare Kidney Diseases (RaDaR) gathers longitudinal data from patients with these conditions, which we used to study disease progression and outcomes of death and kidney failure. Methods People aged 0–96 years living with 28 types of rare kidney diseases were recruited from 108 UK renal care facilities. The primary outcomes were cumulative incidence of mortality and kidney failure in individuals with rare kidney diseases, which were calculated and compared with that of unselected patients with chronic kidney disease. Cumulative incidence and Kaplan–Meier survival estimates were calculated for the following outcomes: median age at kidney failure; median age at death; time from start of dialysis to death; and time from diagnosis to estimated glomerular filtration rate (eGFR) thresholds, allowing calculation of time from last eGFR of 75 mL/min per 1·73 m2 or more to first eGFR of less than 30 mL/min per 1·73 m2 (the therapeutic trial window). Findings Between Jan 18, 2010, and July 25, 2022, 27 285 participants were recruited to RaDaR. Median follow-up time from diagnosis was 9·6 years (IQR 5·9–16·7). RaDaR participants had significantly higher 5-year cumulative incidence of kidney failure than 2·81 million UK patients with all-cause chronic kidney disease (28% vs 1%; p<0·0001), but better survival rates (standardised mortality ratio 0·42 [95% CI 0·32–0·52]; p<0·0001). Median age at kidney failure, median age at death, time from start of dialysis to death, time from diagnosis to eGFR thresholds, and therapeutic trial window all varied substantially between rare diseases. Interpretation Patients with rare kidney diseases differ from the general population of individuals with chronic kidney disease: they have higher 5-year rates of kidney failure but higher survival than other patients with chronic kidney disease stages 3–5, and so are over-represented in the cohort of patients requiring kidney replacement therapy. Addressing unmet therapeutic need for patients with rare kidney diseases could have a large beneficial effect on long-term kidney replacement therapy demand. Funding RaDaR is funded by the Medical Research Council, Kidney Research UK, Kidney Care UK, and the Polycystic Kidney Disease Charity

Report of progress in peat development,

Mode of access: Internet

Antioxidant enzymes as biomarkers of environmental stress in oysters in Port Curtis

The estuarine embayment of Port Curtis is Queensland's largest multi-cargo port and the fifth largest port in Australia. It supports major industries in the Gladstone area including the world's largest alumina refinery and Australia's largest aluminium smelter. Because the estuary is one of the Coastal CRC's three key study areas, research by the CRC contaminants team focused firstly on identifying contaminants of concern in a screening-level risk assessment. Although enrichment of some metals in marine organisms was recorded, subsequent projects focused on assessment of organism health to determine if environmental harm had occurred. There was a need to demonstrate a relationship between exposure to a contaminant and an adverse ecological effect. The objective of the current study was to examine the use of biomarkers as a measure of pollution-induced stress in oysters (Saccostrea glomerata) transplanted into Port Curtis from a clean area. Biomarkers are defined as a biological response that can be related to exposure to an environmental contaminant. In a broad context they can include measuring such endpoints as reproduction and growth, or behavioural changes; however, the biomarkers chosen in this study measured effects at a cellular level. Exposure to pollutants causes the production of potent oxidants and free radicals capable of damaging important cell components such as proteins and DNA. In response, the cell initiates antioxidant enzyme systems and produces free radical scavengers in order to prevent cellular injury and maintain cell homeostasis. The induced biomarker response can then be measured and related to measured concentrations of the contaminant the oyster is exposed to

Thigh-length compression stockings and DVT after stroke

Controversy exists as to whether neoadjuvant chemotherapy improves survival in patients with invasive bladder cancer, despite randomised controlled trials of more than 3000 patients. We undertook a systematic review and meta-analysis to assess the effect of such treatment on survival in patients with this disease